Centogene (CNTG) Stock Price, News & Analysis

Company Overview

Centogene N.V., together with its subsidiaries, provides pharmaceutical solutions and diagnostic tests in Europe, the Middle East, North America, Latin America, and the Asia Pacific. The company offers data-driven answers to patients, physicians, and pharmaceutical companies for rare and neurodegenerative diseases. It provides CENTOGENE MOx 2.0, a single-step multiomic solution that combines DNA sequencing, biochemical testing, and RNA sequencing; CentoCloud, a cloud-based Software as a Service platform, which enables laboratories to analyze, interpret, and report genomic variants for rare disease diagnostics; FilterTool, a web-based application for genetic data interpretation; and NEW CentoGenome, a Next Generation Sequencing (NGS)-based assay that provides diagnostic information to accelerate access to potential treatment options. The company also offers target and drug screening, clinical development, and market access and expansion, as well as CENTOGENE Biodatabank licenses and insight reports. In addition, it provides early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring; and genetic sequencing and diagnostics services, such as whole exome sequencing, whole genome sequencing, and multiomic testing solutions to physicians, laboratories, and hospitals directly or through distributors. The company was founded in 2006 and is headquartered in Rostock, Germany.

Key Stats

• Today's Range: N/A
• 50-Day Range: $0.07 to $0.35
• 52-Week Range: N/A
• Volume: 8.36 million shs
• Average Volume: 150,868 shs
• Market Capitalization: $8.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

CNTG Stock Analysis - Frequently Asked Questions

How were Centogene's earnings last quarter?

Centogene (NASDAQ:CNTG) posted its earnings results on Wednesday, November, 24th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.59) by $0.49. The business earned $35.60 million during the quarter, compared to analysts' expectations of $31.91 million.

When did Centogene IPO?

Centogene (CNTG) raised $60 million in an IPO on Thursday, November 7th 2019. The company issued 4,000,000 shares at $14.00-$16.00 per share. SVB Leerink and Evercore ISI acted as the underwriters for the IPO and Baird and BTIG were co-managers.

What other stocks do shareholders of Centogene own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Centogene investors own include Avino Silver & Gold Mines (ASM), Avino Silver & Gold Mines (ASM), Lincoln National (LNC), Advanced Micro Devices (AMD), Applied Genetic Technologies (AGTC), Catalyst Pharmaceuticals (CPRX) and Fulcrum Therapeutics (FULC).

Company Calendar

• Last Earnings: 11/24/2021
• Today: 4/07/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Medical laboratories
• Sub-Industry: Healthcare
• Current Symbol: NASDAQ:CNTG
• CIK: 1757097
• Web: www.centogene.com
• Phone: 38180113500
• Fax: N/A
• Employees: 810
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.02
• Quick Ratio: 0.96

Sales & Book Value

• Annual Sales: $48.54 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($1.01) per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 27,080,000
• Free Float: N/A
• Market Cap: $8.80 million
• Optionable: Not Optionable
• Beta: -0.67